R
Robert Knight
Researcher at Celgene
Publications - 158
Citations - 17643
Robert Knight is an academic researcher from Celgene. The author has contributed to research in topics: Lenalidomide & Multiple myeloma. The author has an hindex of 47, co-authored 156 publications receiving 16619 citations. Previous affiliations of Robert Knight include Frankston Hospital & University of Utah.
Papers
More filters
Journal ArticleDOI
Lenalidomide plus Dexamethasone for Relapsed or Refractory Multiple Myeloma
Meletios A. Dimopoulos,Andrew Spencer,M. Attal,H. Miles Prince,Jean Luc Harousseau,Anna Dmoszynska,Jesús F. San Miguel,Andrzej Hellmann,Thierry Facon,Robin Foà,Alessandro Corso,Zvenyslava Masliak,Marta Olesnyckyj,Zhinuan Yu,John Patin,Jerome B. Zeldis,Robert Knight +16 more
TL;DR: Lenalidomide plus dexamethasone is more effective than high-dose dexamETHasone alone in relapsed or refractory multiple myeloma.
Journal ArticleDOI
Lenalidomide plus Dexamethasone for Relapsed Multiple Myeloma in North America
Donna M. Weber,Christine Chen,Ruben Niesvizky,Michael Wang,Andrew Belch,Edward A. Stadtmauer,David S. Siegel,Ivan Borrello,S. Vincent Rajkumar,Asher A. Chanan-Khan,Sagar Lonial,Zhinuan Yu,John Patin,Marta Olesnyckyj,Jerome B. Zeldis,Robert Knight +15 more
TL;DR: Lenalidomide plus dexamethasone is superior to placebo plus DexamethAsone in patients with relapsed or refractory multiple myeloma.
Journal ArticleDOI
Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion.
Alan F. List,Gordon W. Dewald,John M. Bennett,A. Giagounidis,Azra Raza,Eric J. Feldman,Bayard L. Powell,Peter L. Greenberg,Deborah A. Thomas,Richard Stone,Craig B. Reeder,Kenton Wride,John Patin,Michele Schmidt,Jerome B. Zeldis,Robert Knight +15 more
TL;DR: Lenalidomide can reduce transfusion requirements and reverse cytologic and cytogenetic abnormalities in patients who have the myelodysplastic syndrome with the 5q31 deletion.
Journal ArticleDOI
Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia
Eytan M. Stein,Eytan M. Stein,Courtney D. DiNardo,Daniel A. Pollyea,Amir T. Fathi,Gail J. Roboz,Gail J. Roboz,Jessica K. Altman,Richard Stone,Daniel J. DeAngelo,Ross L. Levine,Ian W. Flinn,Hagop M. Kantarjian,Robert H. Collins,Manish R. Patel,Arthur E. Frankel,Anthony S. Stein,Mikkael A. Sekeres,Ronan T. Swords,Bruno C. Medeiros,Christophe Willekens,Christophe Willekens,Paresh Vyas,Alessandra Tosolini,Qiang Xu,Robert Knight,Katharine E. Yen,Sam Agresta,Stéphane de Botton,Stéphane de Botton,Martin S. Tallman,Martin S. Tallman +31 more
TL;DR: Inducing differentiation of myeloblasts, not cytotoxicity, seems to drive the clinical efficacy of enasidenib, a first-in-class, oral, selective inhibitor of mutant-IDH2 enzymes.
Journal ArticleDOI
Efficacy of Pamidronate in Reducing Skeletal Events in Patients with Advanced Multiple Myeloma
James R. Berenson,Alan Lichtenstein,Lester Porter,Meletios A. Dimopoulos,Roldolfo Bordoni,Sebastian George,Allan Lipton,Alan Keller,O. F. Ballester,Michael J. Kovacs,Hilary A. Blacklock,Richard Bell,Joseph F. Simeone,Dirk J. Reitsma,Maika Heffernan,John J. Seaman,Robert Knight +16 more
TL;DR: Monthly infusions of pamidronate provide significant protection against skeletal complications and improve the quality of life of patients with stage III multiple myeloma.